Table 1.
Odds ratios at univariate and multivariate analyses of metastatic colorectal cancer patients who were evaluable for response rate (RR) with oxaliplatin retreatment. Keys: SD = stable disease; PR = partial response; CR = complete response; PD = progressive disease; St.Dev = standard deviation; OR = odds ratio. * = statistically significant.
| Characteristic | Variables | SD + PD | PR + CR | OR (Univariable) | OR (Multivariable) |
|---|---|---|---|---|---|
| Primary tumor location | Right colon | 24 (77.4) | 7 (22.6) | - | - |
| Left colon and rectal | 56 (78.9) | 15 (21.1) | 0.92 (0.34–2.66, p = 0.870) | - | |
| Stage at initial diagnosis | Stage II | 7 (63.6) | 4 (36.4) | - | - |
| Stage III | 31 (77.5) | 9 (22.5) | 0.51 (0.12–2.29, p = 0.355) | 0.36 (0.07–1.93, p = 0.219) | |
| Stage IV | 42 (82.4) | 9 (17.6) | 0.37 (0.09–1.67, p = 0.177) | 0.44 (0.09–2.22, p = 0.300) | |
| Age at initial diagnosis | Mean (St.Dev.) | 55.3 (11.6) | 57.6 (10.6) | 1.02 (0.98–1.06, p = 0.406) | - |
| Gender | Male | 44 (75.9) | 14 (24.1) | - | - |
| Female | 36 (81.8) | 8 (18.2) | 0.70 (0.25–1.82, p = 0.470) | 0.72 (0.25–2.01, p = 0.537) | |
| KRAS status | Wild type | 40 (72.7) | 15 (27.3) | - | - |
| Mutant | 37 (84.1) | 7 (15.9) | 0.50 (0.18–1.34, p = 0.181) | 0.38 (0.12–1.14, p = 0.096) | |
| Number of intervening treatments * | 0–1 | 34 (70.8) | 14 (29.2) | - | - |
| ≥2 | 46 (85.2) | 8 (14.8) | 0.42 (0.15–1.10, p = 0.083) | 0.28 (0.09–0.84, p = 0.028) | |
| Third drug concomitant to oxaliplatin retreatment | No | 58 (79.5) | 15 (20.5) | - | - |
| Yes | 22 (75.9) | 7 (24.1) | 1.23 (0.42–3.35, p = 0.691) | 0.52 (0.14–1.73, p = 0.303) | |
| Line of oxaliplatin retreatment | 0–2 | 36 (75.0) | 12 (25.0) | - | - |
| ≥3 | 44 (81.5) | 10 (18.5) | 0.68 (0.26–1.76, p = 0.428) | - | |
| First oxaliplatin-based regimen setting | Adjuvant | 38 (71.7) | 15 (28.3) | - | - |
| Metastatic | 42 (85.7) | 7 (14.3) | 0.42 (0.15–1.11, p = 0.091) | 0.31 (0.08–1.05, p = 0.066) |